Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014–2017

Patients with hyperuricemia and gout are at an increased risk for cardiovascular (CV) disease. Inhibition of the xanthine oxidase with allopurinol or febuxostat have become the mainstay for urate lowering therapy. However, it has been suggested that febuxostat increases the risk for CV mortality as...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisshaar, Stefan, Litschauer, Brigitte, Reichardt, Berthold, Gruber, Felix, Leitner, Stefan, Sibinovic, Sasa, Kossmeier, Michael, Wolzt, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Comorbidities
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349126/
https://www.ncbi.nlm.nih.gov/pubmed/35589988
http://dx.doi.org/10.1007/s00296-022-05139-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349126/
https://www.ncbi.nlm.nih.gov/pubmed/35589988
http://dx.doi.org/10.1007/s00296-022-05139-8

Ejemplares similares